Neuropeptide Y and Alcoholism: Genetic, Molecular, and Pharmacological Evidence


  • Supported by NIH Grants AA10005 and AA13341 and a VA merit grant (SCP); NIH Grants AA10707 and AA07611 (LGC); Swedish Medical Research Council Grant K2001-21X-10872 (MH); The Finnish Foundation of Alcohol Research (EI); and NIH Grants AA00258 and AA13573 (TET).

Subhash C. Pandey, PhD, Department of Psychiatry, University of Illinois at Chicago, and VA Chicago Health Care System (West Side Division), 820 S. Damen Ave. (M/C 151), Chicago, IL 60612; Fax: 312-569-8114; E-mail:


This article presents the proceedings of a symposium presented at the combined meeting of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, held in San Francisco, CA, in June 2002. The organizers and chairpersons were Subhash C. Pandey and Todd E. Thiele. The presentations were (1) Altered ethanol-induced sedation and ethanol drinking in mutant mice lacking specific NPY receptor, by Todd E. Thiele; (2) NPY in P and NP rats: polymorphism and mRNA expression, by Lucinda G. Carr; (3) The cAMP-dependent PKA in the central amygdala regulates alcohol intake through NPY gene, by Subhash C. Pandey; (4) Involvement of NPY in alcohol dependence: from animal models to human genetics, by Markus Heilig; and (5) Association of neuropeptide Y polymorphism with the occurrence of type 1 and type 2 alcoholism, by Erkki Ilveskoski.